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Abstract
Fibrosis is a progressive and potentially fatal process that can occur in numerous organ systems. Characterised by
the excessive deposition of extracellular matrix proteins such as collagens and fibronectin, fibrosis affects normal
tissue architecture and impedes organ function. Although a considerable amount of research has focused on the
mechanisms underlying disease pathogenesis, current therapeutic options do not directly target the pro-fibrotic
process. As a result, there is a clear unmet clinical need to develop new agents. Novel findings implicate a role
for epigenetic modifications contributing to the progression of fibrosis by alteration of gene expression profiles.
This review will focus on DNA methylation; its association with fibroblast differentiation and activation and the
consequent buildup of fibrotic scar tissue. The potential use of therapies that modulate this epigenetic pathway
for the treatment of fibrosis in several organ systems is also discussed.
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Introduction
Defined by the pathological accumulation of extracellular
matrix (ECM) proteins, fibrosis results in scarring and
thickening of the affected tissue. In essence, fibrosis is an
exaggerated wound healing response which interferes with
normal organ function.
Fibrosis is a characteristic feature of many chronic
diseases that result in end-stage organ failure [1]. In the
developed world, these fibrotic-driven diseases are a
major cause of morbidity and mortality, accounting for
45 % of all deaths [2]. The primary pathways associated
with tissue injury and the development of disease are
relatively well-studied. Despite this, the precise molecular
mechanisms underlying aberrant healing and fibrosis re-
main poorly understood. Effective anti-fibrotic therapies
to prevent rapid disease progression are currently limited.
The process of tissue repair is complex. Tight regula-
tion of ECM synthesis and degradation ensures normal
tissue architecture. This necessary process can, how-
ever, lead to a progressive irreversible fibrotic response
if tissue injury is severe/repetitive or if the wound heal-
ing response itself becomes deregulated [3].
Fibrosis has diverse etiologies where several factors can
be associated with the progression of disease. Regardless
of the initiating factor, all fibrotic diseases converge upon
a final common pathway leading to fibroblast activation
with resultant remodelling of the tissue [4].
The fibroblast: wound healing or fibrosis
Fibroblasts are mesenchymal cells responsible for the
synthesis of ECM components including collagens, fi-
bronectin and elastin [5]. Under normal physiological
conditions, fibroblasts are vital in maintaining the
structural integrity of organs. In response to tissue in-
jury, these cells are activated by pro-fibrotic cytokines
and undergo a change in phenotype from normal rela-
tively quiescent cells involved in slow turnover of ECM
to highly proliferative and contractile myofibroblasts.
Myofibroblasts, characterised by expression of the con-
tractile protein alpha smooth muscle actin (αSMA),
regulate connective tissue remodelling by combining
the ECM synthesising features of fibroblasts with cyto-
skeletal characteristics of contractile smooth muscle
cells [6–8]. In normal repair processes, the myofibro-
blast responses are diminished as the repair resolves to
form a scar, occurring predominantly by apoptosis of
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these hyperactive cells or by reversion back to a more
quiescent fibroblast phenotype [8-10]. During patho-
logical fibrosis, however, these myofibroblasts persist in
tissue resulting in fibrosis and hence impair normal
organ functions.
Evidence suggests that myofibroblasts associated with
disease pathogenesis have several origins with the major
contribution arising from increased proliferation of resi-
dent fibroblasts. Several other sources have been suggested
that are reviewed in detail by McAnulty [11].
Regardless of the origin of myofibroblasts, it appears
that there is a persistent phenotypic change in the fibro-
blast inhibiting the apoptosis or reversion to a resting
phenotype that occurs during the resolution phase of
normal wound healing responses. This idea is supported
by ex vivo work showing that fibroblasts isolated from fi-
brotic tissue maintain their hyperactive phenotype in the
absence of a pro-fibrotic environment [12, 13].
Factors that promote fibroblast differentiation and ac-
tivation, such as growth factors and cytokines, are well
studied; however, the mechanisms that contribute to the
maintenance of the pro-fibrotic myofibroblast phenotype
are less understood. One mechanism that may account
for the permanent hyperactive switch in fibroblasts is
epigenetic modification of gene expression.
Epigenetics
Epigenetics, the study of heritable changes in genome
function that do not alter the nucleotide sequence, plays
an important role in the regulation of gene expression.
Modifications include DNA methylation, histone modifica-
tions and microRNA alterations. These events are crucial
during early development, play a role in cell differentiation
and have now also been implicated in disease pathogenesis
[14, 15].
DNA methylation
DNA methylation occurs when the carbon 5 on the cyto-
sine ring is methylated in a reaction catalysed by DNA
methyltransferase (DNMT) enzymes, resulting in the for-
mation of 5-methylcytosine (5MeC).
Methylation generally occurs on cytosine residues which
precede a guanosine in the DNA sequence (the CpG di-
nucleotide). These CpGs are often found within proximal
promoter regions and are known as CpG islands. Generally
speaking, CpG island promoters are unmethylated and the
absence of methylation is considered a permissive state for
transcriptional activity. Upon methylation, the transcrip-
tional activity of genes becomes suppressed and this is then
passed on to daughter cells during the cell cycle.
Methylation and 5MeC formation results in transcrip-
tional repression by one of two mechanisms (Fig. 1).
Firstly, by direct interference, 5MeC formation can im-
pede the specific binding of transcription factors to recog-
nition sites in their respective promoters [16]. Several
transcription factors, for example, the cyclic AMP-
dependent activator CREB, E2F, HIF and NFkB, recognise
sequences that contain CpG residues and binding of each
has been shown to be inhibited by methylation [16]. Sec-
ondly, gene silencing may occur by direct binding of spe-
cific transcriptional repressors to methylated DNA. These
methyl-CpG-binding proteins can exert regulation over
the expression of multiple genes via their interaction with
methylated DNA and their association with histone modi-
fying enzymes [17]. MeCP1 and MeCP2 were the first two
protein complexes identified. Following this, several new
proteins including MBD1, MBD2 and MBD4 were de-
scribed. For the most part, these repressor protein com-
plexes bind methylated DNA through their methyl CpG
binding domain (MBD) motif [16].
The relevance of CpG island promoter methylation and
its association with disease development and progression
Fig. 1 Epigenetic regulation of fibrotic gene expression profiles. The absence of DNA methylation permits gene transcription. DNA methylation,
the addition of a methyl group to carbon 5 on the cytosine ring, is catalysed by the DNA methyltransferase enzymes. Methyl binding domain
(MBD) proteins are recruited to methylated DNA and result in gene silencing by preventing transcription factor binding. Several genes associated
with the development of fibrosis, highlighted in the figure, have been shown to undergo silencing as a result of DNA hypermethylation. It is likely that
many other genes yet to be identified are also involved in the epigenetic regulation of fibrosis. These associations suggest the potential use of agents
which target this methylating event for therapeutic use in fibrotic disease
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was first observed in cancer, where DNA methylation si-
lenced important tumour suppressors enabling cancer to
progress [18]. The emerging role of DNA methylation in
fibrosis will be discussed further below.
Demethylation
A relatively novel area of research associated with DNA
methylation and disease pathogenesis, based upon the
recent discovery of the ten-eleven translocation (TET)
family of enzymes (TET1, TET2 and TET3), is now emer-
ging. Whilst the DNMT family of enzymes establish and
maintain DNA methylation, TET enzymes are implicated
in DNA demethylation and epigenetic control of gene ex-
pression [19, 20]. Conventionally, 5MeC formation is as-
sociated with a transcriptionally repressed chromatin state
whilst TET enzyme activity and subsequent demethylation
enables gene transcription to proceed [21]. These enzymes
convert 5MeC to 5-hydroxymethylcytosine (5hmC), which
undergoes subsequent deamination and base excision re-
pair by thymine DNA glycosylase [21]. 5MeC derivatives
can then be recognised and removed by the base excision
repair machinery resulting in the demethylation of once
methylated cytosines. Much less is known about the epi-
genetic modification 5hmC, most likely accounted for by
the difficulty in detecting both global and locus-specific
levels; efficient techniques to achieve this have only been
established in the previous 5 years [22]. The physiological
significance of DNA oxidation in epigenetic regulation
therefore remains poorly understood. With regard to dis-
ease, much like DNA methylation, most findings are asso-
ciated with cancer development and progression [23, 24].
In the context of fibrosis, research is quite limited. Further
work is required for understanding the role of TET pro-
teins and 5hmC in gene regulation and disease.
Interaction of epigenetic modifications
It is becoming increasingly clear that DNA methylation
plays a central role in directing histone modifications,
and regulating micro RNA expression, and thus repre-
sents an important point of interaction between these
epigenetic mechanisms.
Histone proteins are associated with DNA and are im-
portant for chromatin packaging and remodelling. The N-
terminal tails of these proteins undergo post-translational
modifications including acetylation, deacetylation and
methylation which alter their interaction with DNA and
can thus impact gene expression. Although much is still
to be learned, the relationship between DNA methylation
and histone modifications is becoming increasingly clear.
It is now believed that the two mechanisms cooperate in
controlling gene expression. It seems that the relationship
can work in both directions: histone methylation can
help to direct DNA methylation patterns, and DNA
methylation may serve as a template for some histone
modifications after DNA replication. The link between
the two alterations may be partially mediated through
methyl-binding proteins such as MeCPs or MBDs
which are capable of recruiting histone deacetylases to
the methylated region [25].
A bi-directional relationship between DNA methyla-
tion and non-coding RNAs (ncRNA) has also recently
been highlighted. ncRNAs are functional molecules
transcribed from DNA but not translated into proteins.
In general, these molecules function to regulate gene ex-
pression at the transcriptional and post-transcriptional
level. ncRNAs that appear to be involved in epigenetic
processes are divided into two main groups: the short nc-
RNAs (<30 nts) and the long nc-RNAs (> 200nts). Micro-
RNAs (miRNA) are perhaps the most well known of the
regulatory ncRNA classes and have been shown to play a
role in heterochromatin formation, DNA methylation
targeting and gene silencing. miRNAs comprise a class of
short ncRNAs, 18–25 nucleotides in length, which regulate
gene expression post-transcriptionally. These miRNAs
bind to the 3′UTR of their target genes and control gene
expression by translational suppression and/or destabilisa-
tion and degradation of the target gene. Interestingly, each
miRNA is predicted to have many targets, and each mRNA
may be regulated by more than one miRNA [26]. Epigen-
etic mechanisms, including DNA methylation and histone
modifications regulate the expression of some miRNAs.
Conversely, another subset of miRNAs can control the ex-
pression of important epigenetic regulators, including the
DNA methyltransferase and histone deacetylase enzymes.
This complicated network of feedback between miRNAs
and epigenetic pathways appears to form an epigenetics,
miRNA regulatory circuit, and is important in organising
the whole gene expression profile. Disruption of this circuit
interferes with normal, physiological functions and can
contribute to disease processes [26, 27].
A clear example of the relationship between DNA
methylation and miRNA expression occurs rather interest-
ingly in a study looking at pulmonary fibrosis. Dakhlallah
et al. highlight a miRNA-DNMT regulatory circuit. This
work identified reduced expression of miR17~92 which
was associated with increased DNMT-1 and a pro-fibrotic
phenotype. The authors showed that several miRNAs
from the miR17~92 cluster targeted DNMT-1 expression
resulting in a negative feedback loop [28].
Given these associations, it is likely that multiple inter-
actions involving several epigenetic modifications contrib-
ute to the pathogenesis of many diseases.
Epigenetics and disease
The role of epigenetics in disease is perhaps most well
documented in the case of cancer whereby DNA hyper-
methylation and subsequent silencing of tumour sup-
pressor genes allows rapid disease progression. Although
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much less common, hypomethylation can also occur
activating the aberrant expression of oncogenes [29–31].
DNA hypomethylation due to alterations in the demeth-
ylation machinery have been identified in cancer. TET
enzymes are mutated in several types of cancer, affecting
their activity and likely altering genomic 5hmC and 5MeC
patterns [24].
Histone modifications and microRNA alterations have
also been implicated in numerous disease processes [32].
Similar to DNA methylation, these are most evident in
the setting of cancer.
Given these pathological associations, inhibiting epi-
genetic processes has become apparent as a potential
therapeutic target. Epigenetic therapies are now used as
treatment options in some cancers. Inhibitors of DNA
methylation as well as histone deacetylase inhibitors
(vorinostat and romidepsin) have been FDA approved
for the treatment of certain malignancies. Although an
miRNA targeting agent has yet to be approved, this field
of research is expanding exponentially. miRNAs have not
only shown promise in the field of drug development but
have also shown potential as effective biomarkers in a
number of different clinical scenarios [33].
Inhibiting DNA methylation
5-azacytidine (5-aza; Vidaza) and 5-aza-2-deoxycytidine
(5-azadC; Decitabine) are demethylating agents that are
effective for the treatment of myelodysplasic syndromes
(MDS) and acute myeloid leukaemia (AML) [34, 35].
These compounds are internalised by cells and incorpo-
rated into DNA. Covalent adducts with cellular DNMT1
are formed thereby depleting enzyme activity and inhibit-
ing methylation of DNA during cell division [36].
Re-expression of epigenetically silenced tumour sup-
pressor genes is a rational strategy for the treatment of
human neoplasms with these epigenetic modifiers.
Nonetheless, the mechanism of action behind their
clinical efficacy remains unclear. Ongoing clinical trials
are attempting to identify tumour suppressor genes that
upon re-expression can induce remission and cure in
patients. On the other hand, the pleiotropic biological
effects of DNMT inhibitors and recent reports demon-
strating lack of association between clinical response and
methylation reversal of candidate tumour suppressor
genes, suggest a complex mechanism behind their clinical
efficacy that may involve a cytotoxic effect [37, 38].
Although these compounds have demonstrated bene-
ficial clinical effects, there are some drawbacks relating
to their use. Epigenetic modifications, such as DNA
methylation, are important in normal physiology; thus,
inhibiting this process is likely to yield some unwanted
side effects. Adverse effects such as nausea, vomiting, diar-
rhoea and loss of appetite have been observed. Myelosup-
pression is another major side effect that occurs upon
treatment with 5-aza/5-azadC. Most patients recover
within a 5–6-week period; however, this does limit dose
and duration of treatment [39].
It is also apparent that the half-life of DNA demethylat-
ing agents is quite short; hence, the development of 5-aza
therapeutic strategies for the treatment of fibrotic patholo-
gies as opposed to blood malignancies would require in-
vestigations into drug formulations which could improve
efficacy as an anti-fibrotic agent. Such approaches that
could be explored include controlled release preparations
and pro-drug formulation approaches to optimise bio-
availability and increase the therapeutic window for the
hypomethylation indication. Unlike in cancer, a sustained
low-dose release may be more beneficial for the treatment
of fibrosis, avoiding high cytotoxic doses. Furthermore, it
would be of value if new formulations could be devised
that enable specific organs to be targeted depending on
the fibrotic pathology. Some of these approaches are being
pursued, including oral formulations [40, 41] and target-
able drug loaded biodegradable microspheres [42–44].
Whilst aberrant epigenetic modifications are most widely
studied in the context of cancer, they have been identified
to play a role in the development of several other disease
pathologies. Recent reports highlight a growing link be-
tween epigenetic modifications and fibrosis. The approval
of epigenetic drugs in cancer holds promise for the use of
these agents as effective therapeutics for the treatment of
several different diseases. Although in vitro and in vivo
work on the associations between epigenetic modifications
and the pathogenesis of fibrosis are constantly emerging,
as of yet, there are no clinically approved epigenetic ther-
apies to treat fibrotic diseases. Given that DNA methyla-
tion is the principal focus of this review, we will go on to
describe the associations and role of this alteration in the
progression of fibrosis in the following section.
DNA methylation and fibrosis
It has been hypothesised that maintenance of the acti-
vated state of the myofibroblast during fibrotic disease
reflects a failure to return to its resting state as in nor-
mal physiological wound healing. During the process of
differentiation, active myofibroblasts acquire significant
changes in their gene expression profiles [45]. Whilst
various environmental features within the injured tissue
are likely to be involved in promoting fibroblast differenti-
ation, it is proposed that stable changes in gene expression
due to chromatin modifications are responsible for the
sustained myofibroblast phenotype [46]. Understanding
the epigenetic mechanisms by which fibroblasts acquire
these pro-fibrotic phenotypes and subsequently differ-
entiate to myofibroblasts is important for complete
elucidation of the pathogenesis of fibrosis as well as its
management and treatment.
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Pulmonary fibrosis
A role for DNA methylation in regulating fibroblast
phenotype during disease progression is supported in sev-
eral studies. Gene-specific hypermethylation events as well
as global changes in DNA methylation have been identi-
fied in a number of organ systems. Two genomic studies
comparing the profile of lungs from normal and idiopathic
pulmonary fibrosis (IPF) patients revealed extensive DNA
methylation changes, thus implicating DNA methylation
in the control of IPF lung gene expression [47, 48]. It is
also important to consider the fact that epigenetic modifi-
cations may not be homogeneous across organ fibroblast
populations and in some fibrotic pathologies; it has been
acknowledged that sub-populations of fibroblasts exist
characterised by distinct cellular phenotypes. This is par-
ticularly well documented in the lung where fibroblasts,
depending on their expression of certain genes, have more
or less potential to differentiate into highly proliferative,
contractile myofibroblasts. One candidate gene that is im-
plicated in the epigenetic control of fibroblast phenotype
is thymocyte differentiation antigen-1 (Thy-1). Thy-1 has
been implicated in controlling the activation of the latent
form of the pro-fibrotic growth factor transforming
growth factor beta 1 (TGF-β1) and represents a potentially
important anti-fibrotic gene [49, 50]. Diminished Thy-1
expression is associated with a more fully differentiated
myofibroblast phenotype, potentially due to exaggerated
TGF-β1 signalling, and fibrotic tissue buildup [45], [51].
Loss of Thy-1 is observed in lung tissue from patients with
IPF where reduced expression of Thy-1 in active myofi-
broblast clusters, known as fibroblastic foci, was shown to
be due to promoter methylation. Reduced expression of
this anti-fibrotic gene was one of the first demonstrations
of the importance of epigenetics in fibrosis [52]. Interest-
ingly, a study by Robinson et al. showed that hypoxia,
which has previously been implicated in the pathogenesis
of pulmonary fibrosis, promotes global DNA hypermethy-
lation as well as Thy-1 gene-specific hypermethylation in
primary human lung fibroblasts. Thy-1 gene expression
was suppressed in these hypoxic fibroblasts but could be
restored by treatment with the DNMT inhibitor 5aza-2′
deoxycytidine (5azadC) [53].
Prostaglandin E receptor 2 expression (PTGER2) has
also been linked with pulmonary fibrosis. Work by Huang
et al. showed that IPF fibroblasts were resistant to the
anti-fibrotic effects of prostaglandin E2. The authors sug-
gested that this may be due to the loss of PTGER2 as a
result of hypermethylation-induced silencing. This was
demonstrated in both IPF fibroblasts and in fibroblasts
from a bleomycin mouse model of fibrosis. Increased glo-
bal DNA methylation was also observed [54].
The persistence of activated myofibroblasts during the
progression of fibrotic responses may be accounted for
by resistance to apoptosis. Epigenetic mechanisms may
play a role in mediating the anti-apoptotic properties of
pro-fibrotic myofibroblasts. P14ARF induces cell cycle ar-
rest. Hypermethylation and subsequent silencing of
P14ARF was shown in IPF patient-derived fibroblasts. This
hypermethylation-induced silencing event may contribute
to pathological lung fibrosis as myofibroblasts may acquire
an anti-apoptotic phenotype. Myofibroblasts can then per-
sist in tissue causing an excess production of ECM [55].
As previously mentioned, a recent exciting study by
Dakhlallah et al. looking at both lung biopsies and fibro-
blasts from IPF patients as well as a bleomycin-induced
pulmonary fibrosis model that highlights a novel epigen-
etic regulatory circuit involving DNMT enzymes and a
miRNA cluster. This work identified elevated expression
of DNMT1 which was associated with diminished expres-
sion of a miRNA cluster and a pro-fibrotic phenotype.
Interestingly, in this study, and in all cases described
above, treatment with the DNA methylation inhibitors 5-
azacytidine (5aza) or 5-azadC restored expression of the
miRNA or of the gene in question and reduced fibrosis.
Renal fibrosis
DNA methylation has also been implicated in the patho-
genesis of renal fibrosis. A genome-wide study investigat-
ing cytosine methylation patterns in healthy and chronic
kidney disease patient samples identified significant differ-
ences. A core set of genes known to be related to kidney
fibrosis, including those encoding collagens, showed cyto-
sine methylation changes correlating with downstream
transcript levels, thus implicating a role for epigenetic dys-
regulation in chronic kidney disease development [56].
In a separate study by Bechtel et al., a gene-specific
hypermethylation event was eluded to in the case of Ras
GTPase activating-like protein 1 (RASAL1). RASAL1 ex-
pression was decreased in the kidneys of a folic-acid
induced fibrotic mouse model. This hypermethylation-
induced silencing of RASAL1 was associated with increased
DNMT1 expression. In support of this, DNMT1+/− mice
when compared with wild-type controls exhibited reduced
renal fibrosis when challenged with folic acid. The DNA
methylation inhibitor 5-aza also displayed beneficial effects
in the kidney where the fibrotic fibroblast phenotype was
normalised in vitro and experimental murine renal fibrosis
ameliorated [57].
The research mentioned thus far implicates DNA
methylation in the fibrotic response and alludes to the
potential use of DNMT inhibitors as viable therapeutics.
It is interesting to note that associations between DNA
demethylation, TET enzyme activity and fibrosis have
also been uncovered. A recent study by Tampe et al.
alludes to a potential novel role for demethylation and
TET enzymes in the treatment of renal fibrogenesis. In
this study, renal fibrosis was again associated with
RASAL1 hypermethylation and subsequent suppression.
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Interestingly, this work also demonstrated loss of TET3
expression during disease progression. Application of
BMP7, which has endogenous anti-fibrotic effects through
TGF-β1 antagonism, to pro-fibrotic renal fibroblasts was
associated with induction of TET3, normalisation of
RASAL1 promoter methylation and restored RASAL1 ex-
pression [58]. This work reveals a new mechanism which
may be exploited to facilitate therapeutic DNA demethyla-
tion to reverse kidney fibrosis.
Liver fibrosis
Interestingly, RASAL1 methylation has also been corre-
lated with fibroblast differentiation in rat hepatic stellate
cells. Hypermethylation of RASAL1 was associated with
the perpetuation of fibroblast activation and fibrogenesis
in the liver. Treatment with 5-azadC reduced fibroblast
proliferation and restored RASAL1 expression [46]. This
work by Tao et al. also suggests an additional epigenetic
control mechanism of fibrosis.
As alluded to previously, recruitment of proteins which
bind methylated DNA affects gene expression. Although
slightly contradictory, MeCP2, has now been shown to
play a pivotal role in the development of fibrosis and
fibroblast differentiation. During liver fibrosis, hepatic stel-
late cells (HSCs) become activated and undergo myofibro-
blast transdifferentiation; expression of MeCP2 is altered
during this process. Induction of MeCP2 during HSC
activation contributes to the loss of expression of several
anti-fibrotic mediators including RASAL1 and peroxisome
proliferator-activated receptor gamma (PPARλ) [59, 60].
These findings are backed up by in vivo studies. In a rat
model of hepatic fibrosis, MeCP2 expression was in-
creased compared with healthy controls [46]. In a separate
in vivo study looking at pulmonary fibrosis, myofibroblast
differentiation was attenuated in MeCP2−/− mice [61].
This work similarly suggests a positive relationship be-
tween MeCP2 expression and the development of fibrosis,
but the authors of this study focus on pro-fibrotic αSMA
expression. Loss of MeCP2 in this case resulted in de-
creased expression of the myofibroblast marker in both
mouse lung fibroblasts and in vivo in a bleomycin murine
model of pulmonary fibrosis. The authors in this paper
link reduced MeCP2 with reduced fibrosis due to pro-
fibrotic (αSMA) gene silencing. Whilst both studies
support a pro-fibrotic function for MeCP2, these data sug-
gest an alternate mechanism to the work carried out by
Tao et al. who associate reduced MeCP2 with reduced
methylation, hence transcriptional activation of anti-
fibrotic RASAL1/PPARλ. These findings suggest that the
effects of transcriptional repression by MeCP2 may be
gene-/species-dependent or that perhaps complete knock-
out of MeCP2 has knock-on effects on other associated
pathways which may contribute to the effects on αSMA
expression.
In addition to the gene-specific methylation events
highlighted above, work examining the genome-wide
DNA methylation status in early stage liver fibrosis has
also been carried out. Although the aforementioned
work primarily implicates DNA hypermethylation in
the development of a fibrotic phenotype, rather inter-
estingly early stage liver disease was associated with
global DNA hypomethylation [62]. Comparing control
and early stage fibrotic livers, the authors’ identified
reduced genome-wide DNA methylation in a mouse
model of carbon tetrachloride-induced fibrosis. Further-
more, a gene-specific hypomethylation event in the case
of secreted phosphoprotein1 (Spp1) gene, a known in-
ducer of inflammation, was also alluded to. These results
suggest that DNA hypomethylation may be crucial for the
onset and initial triggering of liver fibrosis. Hypomethyla-
tion and the resultant increased expression of genes in-
volved in the initiation of fibrosis, such as Spp1, may
precede the onset of liver fibrosis. The authors suggest the
potential involvement of a switch from hypo- to hyperme-
thylation during the development and progression of liver
fibrosis.
Cardiac fibrosis
Very recent reports now implicate a role for the epigenetic
regulation of cardiac fibrosis. A study by Watson et al.
identified a role for DNA methylation in hypoxia-induced
cardiac fibrosis. Fibroblast exposure to hypoxic conditions
upregulated collagen and αSMA which was associated
with increased global hypermethylation and increased ex-
pression of the DNMT enzymes DNMT1 and DNMT3B
via the hypoxic response transcription factor HIF-1α.
These data were complemented by in vivo evidence of ro-
bust fibrosis in areas of hypoxic myocardium in human
cardiac tissue samples. In addition to this, application of
the DNA methylation inhibitor 5-azadC reduced the
hypoxia-induced activation of myofibroblasts in vitro [63].
A separate study by Tao et al. also alludes to a role for
DNA methylation in the pathogenesis of cardiac fibrosis.
Increased expression of DNMT3a was observed in acti-
vated cardiac fibroblasts and in fibroblasts isolated from
isoprenaline-treated rats. Elevated expression of the methy-
lating enzyme was associated with increased expression of
αSMA and silencing of the tumour suppressor gene RAS-
SAF1A. Therapeutic intervention with 5-aza reduced fibro-
blast expression of pro-fibrotic markers and restored
RASSAF1A gene expression.
Several murine models of cardiac disease now also sup-
port a pathogenic role for DNA methylation in myocardial
fibrosis and highlight beneficial effects upon therapeutic
intervention with inhibitors of this epigenetic process.
A study looking at the mechanisms of cadmium-
induced cardiac dysfunction identified beneficial effects of
5-azadC. Male mice were exposed to cadmium for 4 weeks
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with or without the DNA methylation inhibitor. Cadmium
exposure led to interstitial fibrosis and collagen 1 depos-
ition which was reduced upon intervention with 5-azadC
[64]. In addition, separate work showed that angiotensin
II-induced cardiac fibrosis was reduced upon administra-
tion of 5-aza [65]. Treatment with 5-aza prevented the
accumulation of myocardial collagen in this model. The
spontaneously hypertensive rat has been shown to demon-
strate significant cardiac fibrosis. In a novel study by
Watson et al., intervention with 5-aza reduced both total
and perivascular collagen deposition in the SHR [66],
again highlighting protective effects of the epigenetic
modifying agent and suggesting a potential causal role for
heightened methylation in the fibrotic heart.
Rather interestingly, Zeisburg et al. have recently
identified a gene-specific hypermethylation event in the
case of RASAL1 in cardiac fibrosis (as is evident in
both liver and renal fibrosis). This work demonstrated
aberrant DNA promoter methylation and subsequent
transcriptional silencing of RASAL1 which enhanced
endothelial-mesenchymal transition (EndMT) and myo-
cardial fibrosis. Furthermore, the authors report that
endothelial cells in the heart possess an intrinsic mech-
anism to reverse aberrant DNA promoter methylation
involving TET3-mediated hydroxymethylation. Admin-
istration of anti-fibrotic BMP7 therapeutically induced
TET3-mediated reversal of RASAL1 [67]. These novel
findings provide further proof-in-principle evidence
that aberrant DNA methylation contributes to cardiac
fibrosis and that demethylation may serve as anti-
fibrotic therapeutic strategy in chronic heart disease in
the future.
Whilst the work highlighted above demonstrates pro-
tective effects of inhibiting DNA methylation in several
experimental models of cardiac fibrosis, global levels of
DNA methylation have not been assessed. Interestingly,
this has somewhat been addressed in human studies of
both heart failure and cardiomyopathies where differen-
tial patterns of DNA methylation have been identified
[68, 69]. Although this data is not specific to cardiac fibro-
sis, these pathologies are somewhat associated with the
excessive accumulation of extracellular matrix proteins
and thus suggest the potential for a role of an altered
DNA methylation profile driving fibrotic responses in the
myocardium. This requires further investigation.
Scleroderma
A role for DNA methylation has also been implicated in
scleroderma (systemic sclerosis, SSc). Scleroderma is a
complex multi-system disorder associated with vascular
damage and auto-immunity, ultimately resulting in
fibroblast activation and collagen accumulation in the
skin and internal organs. Genome-wide DNA methyla-
tion analysis in dermal fibroblasts from patients with
systemic sclerosis identified several differentially methyl-
ated genes comparison to healthy matched controls.
Differential DNA methylation patterns were evident in
several genes/pathways known to be associated with fibro-
genesis. These included genes encoding collagen proteins
as well as those involved in the TGFβ1/integrin and Wnt/
β-catenin signalling pathways. Moreover, DNA methyla-
tion status was shown to correlate with gene expression in
the majority of genes evaluated in this study. For the most
part, differentially methylated pro-fibrotic genes displayed
hypomethylated profiles; hence, their expression was in-
creased in SSc compared to controls [70].
In addition to this work which highlights genome-
wide DNA methylation changes in systemic sclerosis, a
separate study looked more specifically at epigenetic
regulation of enhanced collagen expression in scleroderma
fibroblasts. Elevated collagen levels were associated with
increased levels of the DNMT enzymes and methyl bind-
ing proteins in dermal fibroblasts isolated from patients
with systemic sclerosis compared to controls. The authors
first showed that addition of 5-azadC normalised collagen
levels in scleroderma fibroblasts. Following on from this, a
mechanism responsible for increased collagen production
via an epigenetic repressive effect on the collagen suppres-
sor gene FLI1, was identified. Through methylation-
induced silencing of FLI1, the repressive effect on collagen
synthesis was removed, thus permitting increased collagen
gene transcription [71].
Interestingly, alterations in DNA methylation have also
been highlighted in fibroblasts isolated from keloids. Ke-
loids can occur as a result of an overactive dermal wound
healing response. A study using ChIP-Chip analysis and
DNMT inhibitor treatment also allude to an epigenetically
altered programme in fibroblasts isolated from keloid
scars when compared to those isolated from healthy scar
tissue [72].
In light of the abovementioned work highlighting associ-
ations between DNA methylation and a fibrotic phenotype
in several organ systems, together with the beneficial in
vitro and in vivo effects of 5-aza/5-azadC, it seems plaus-
ible to suggest that epigenetic modifying drugs such DNA
methylation inhibitors may demonstrate significant clin-
ical efficacy in treating fibrosis. Of note, however, these
drugs which have displayed anti-fibrotic properties target
enzymes on a global level and may bring about adverse
side effects; therefore, caution must be exerted. Interest-
ingly, in some of the fibrotic conditions highlighted above,
the increase in DNA methylation has been attributed to
specific upregulation of either the maintenance enzyme
DNMT1 or the de novo methyltransferases DNMT3a and
DNMT3b. Although one might expect an increase in
DNMT3a or DNMT3b to be primarily involved in initi-
ating pro-fibrotic DNA methylation patterns, studies in
the liver, lung, heart, kidneys and systemic sclerosis have
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implicated a role for elevated DNMT1 and/or DNMT3 or
DNMT3b in fibrosis [28, 47, 57, 71, 73–75]. These
important observations further highlight the link between
dysregulation of DNMTs and fibrosis and the rationale of
targeting them therapeutically. The current DNMT inhibi-
tors in clinical practice 5-aza and 5-azadC preferentially
target DNMT1 and thus affect the maintenance of DNA
methylation. However, it could be of great value to de-
velop DNMT inhibitors that are specific to de novo
methylating enzymes, given that this enzyme sub-type
is likely responsible for generating new additional methy-
lation marks in the development of fibrosis. Using an in-
hibitor to DNMT3a or DNMT3b rather than DNMT1
may also reduce the likelihood of adverse side effects as
the de novo methylating enzyme levels should be minim-
ally expressed in most mammalian adult tissue types.
Given the complex roles of the DNMT enzymes in initiat-
ing and maintaining disease-relevant DNA methylation
patterns, it is likely that a combination therapy targeting
both the maintenance and the de novo methyltransferases
would be most beneficial. Treating early in disease with a
global DNMT inhibitor could allow pathological cells to
reset their normal DNA methylation pattern but might be
associated with a higher risk of side effects. These side
effects could perhaps be minimised by then maintaining
patients on therapies that specifically target the de novo
DNMTs and do not affect the maintenance of DNA
methylation patterns in healthy tissues. Given that histone
modifications and microRNA changes appear to interact
with DNA methylation, it may be the case that a combin-
ation of epigenetic therapies would be more efficacious.
Although much progress has been made, this area cer-
tainly warrants further investigation into the gene-specific
alterations that occur in fibrotic tissue during disease
progression.
A role for hypoxia in the fibrotic response
As previously alluded to, although the final common
pathway in fibrosis appears to be similar across organ
systems, the initiation event may vary. One recurring
theme contributing to the pathogenesis of fibrotic dis-
ease is hypoxia. Hypoxia occurs when a cell’s demand
for oxygen exceeds supply and can lead to the accumu-
lation of gene expression changes.
Associations between hypoxia, fibrosis and epigenet-
ics are becoming ever apparent. It is likely that cellular
responses to acute hypoxia, which may occur as a conse-
quence of tissue ischemia or increased oxygen consump-
tion, play a crucial role in shaping the wound healing
response. Consistent with a role as a fibrogenic stimulus,
hypoxia stimulates fibroblast proliferation and induces
aSMA expression. This corresponds with increased col-
lagen synthesis in human renal fibroblasts, pulmonary
fibroblasts, cardiac fibroblasts and hepatic stellate cells
[53, 63, 76]. The effects of hypoxia are predominantly de-
scribed as pathological, resulting from the hyperprolifera-
tion of fibroblasts and excessive ECM deposition. In some
cases, however, as is evident in the heart post-myocardial
infarction, hypoxia-induced activation of fibroblasts can
have protective effects. Fibroblast activation and subse-
quent myocardial remodelling is required here to ensure
restoration of normal cardiac structure and function [77].
One mechanism by which hypoxia may influence the
fibroblast phenotype is via the regulation of DNA
methylation [78]. A role for hypoxia modulating the
DNA methylation profile of cells has been described and
is suggested to arise from hypoxic regulation of DNMT
expression [79–81]. Interestingly, there are putative hyp-
oxia responsive elements (HRE) on the promoters of all
three active DNMTs with in vitro data indicating that
hypoxia-induced DNMT1 and DNMT3b promoter activ-
ity is HRE-dependent [63]. As mentioned earlier, studies
in fibroblasts from both the lungs and the heart have
demonstrated hypoxic regulation of DNA methylation.
Robinson et al. showed that culturing human pulmonary
fibroblasts under hypoxic conditions results in a hyper-
methylated phenotype, and this was associated with
methylation-induced silencing of anti-fibrotic Thy-1 [53].
Further supporting a role for hypoxia induced methyla-
tion, work by Watson et al. identified increase gene and
protein expression of both DNMT1 and DNMT3b in
hypoxic human ventricular fibroblasts [63].
Another role for hypoxia in the fibrotic response
arises from its effects on angiogenesis, although the
outcome of this is very much organ-dependent. Hyp-
oxia can promote vessel growth by upregulating mul-
tiple pro-angiogenic pathways [82]. In addition to this,
several genes which play important roles in angiogen-
esis, including EPO and VEGF, are regulated by HIF-1α.
The precise relationship between angiogenesis and fi-
brosis remains controversial as considerable evidence
supports both a positive and negative regulatory role
for angiogenesis in progressive fibrosis. An association
between excessive angiogenesis and fibrosis in IPF has
been suggested based on both human studies and
bleomycin-induced murine pulmonary fibrosis [83, 84].
The development of liver fibrosis is also accompanied
by increased angiogenesis [85]. On the other hand, in-
adequate angiogenesis has been implicated in a model
of interstitial renal fibrosis. In this model, decreased
renal microvascular density is accompanied with pro-
gressive renal impairment, excessive matrix deposition
and interstitial fibrosis [86]. Similarly, reduced extent of
microvasculature is associated with cardiac fibrosis de-
velopment [87]. Given the need to maintain adequate
tissue perfusion and oxygenation, and the negative impact
of fibrosis on this process, it is likely that hypoxic regula-
tion of epigenetic mechanisms such as DNA methylation
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are a central but complex feature of the wound healing re-
sponse and progression to fibrotic disease.
Novel perspectives
There has been an array of additional work highlighting
a role for DNA methylation in the pathogenesis of fibro-
sis. Although very interesting, literature in some of these
areas is still somewhat limited. We have therefore de-
cided to include the following topics in this perspectives
section to draw attention to the work that is being done
in this exciting field of research.
Influence of DNA methylation on heritable susceptibility to
disease
Whilst most of the examples mentioned thus far indicate
a role for DNA methylation in the suppression of anti-
fibrotic gene expression during the progression of disease,
it is interesting to note that there may also be a role for
epigenetics in protecting offspring from fibrotic disease.
The concept that epigenetic signatures can be inher-
ited in an intergenerational fashion is supported by recent
experimental studies. Alterations in the methylation of
germ cell DNA caused by in utero exposure to environ-
mental toxins mediate the transgenerational transmission
of adult-onset pathologies in multiple organs [88]. Re-
searchers from a recent study also reported that feeding
adult male rats a high-fat diet led to insulin resistance in
female offspring that was associated with β cell dysfunc-
tion, and this was linked with gene hypomethylation [89].
Furthermore, feeding a low-protein diet to male mice
altered the global CpG methylation patterns in their off-
spring, and these changes were associated with adaptation
of hepatic lipid and cholesterol metabolism [90].
A link between inherited epigenetic signatures and fi-
brosis has now also been made by Mann et al. who report
a multi-generational epigenetic adaptation of hepatic
wound healing. A role for DNA methylation in the control
of both anti- and pro-fibrotic gene expression is identified.
It was shown that the offspring of rats with liver fibrosis
have reduced fibroblast activation and that these protect-
ive effects are due to an epigenetic suppressive mechan-
ism, suggesting that remodelling of DNA methylation
underpins these gene expression adaptations. Increased
expression of anti-fibrotic PPARλ was shown to be associ-
ated with promoter hypomethylation whilst simultaneous
promoter hypermethylation induced silencing of the pro-
fibrotic growth factor TGF-β1. The adaptive effect on
fibrogenesis was apparent within a single generation but
was more pronounced when liver fibrosis was present in
the successive F0 and F1 generations, which is suggestive
of a cumulative process [91]. Intergenerational downregu-
lation of liver fibrogenesis may therefore have the bio-
logical advantage of ensuring greater fitness of subsequent
generations that are exposed to the environmental pres-
sures of potent liver toxins.
Interestingly, another recent discovery has identified a
link between maternal transmission of DNA methylation
at the promoters of specific circadian clock genes and
the development of hepatic fibrosis [92]. The circadian
clock controls, among others, daily metabolism and sub-
sequent activity rhythms. Rhythmicity is driven by a
circadian timing system composed of a central pace-
maker and master oscillator, the suprachiasmatic nucleus
(SCN), which can also drive self-sustained oscillators in
peripheral cells and tissues [93]. Transcription factors,
which drive the expression of their own negative regula-
tors, are central to the molecular rhythmicity of SCN
neurons and oscillating cells [94]. This transcriptional
feedback loop is regulated by complex mechanisms, in-
cluding post-translational modifications of circadian pro-
teins, which both maintain clock timing and enable
adjustments to the clock machinery based on changes in
the environment [95, 96]. Interestingly, epigenetics have
also been shown to play an important role in the tran-
scriptional activation of clock gene machinery, which
relies on chromatin remodelling [97]—detailed discus-
sion on this topic is beyond the scope of this review.
Returning to the subject of maternal transmission of
altered DNA methylation patterns, and their subsequent
contribution to fibrosis, a study by Mouralidarane et al.
showed that offspring from obese mothers displayed dis-
rupted daily expression of both α-SMA and TGF-β1.
Peak expression of both pro-fibrotic markers was ob-
served predominantly close to or in the dark phase—the
period of maximal rodent activity. The authors alluded
to the fact that repair and regeneration, which normally
occur during rest cycles (i.e. during the day), were
compounded in the activity period, and this may have
enhanced the development of fibrosis. They therefore sug-
gest that the development of hepatic fibrosis in offspring
from obese mothers may arise from desynchronisation of
normal rhythmic expressions of these fibrosis-inducing
genes. Further experiments noted that the deregulated
expression α-SMA and TGF-β1 was associated with al-
tered gene expression of two genes involved in circadian
clock homeostasis, namely BMAL1 and Per2. DNA
methylation analysis at the promoter region of both genes
identified a hypermethylated profile, which may account
for the corresponding changes in BMAL1 and Per2 gene
expression. This altered circadian clock gene expression,
as a result of promoter hypermethylation, may in turn
affect the disrupted daily expression of genes involved in
fibrogenesis thus resulting in the development of a fibrotic
phenotype.
In addition to this work, a growing body of evidence
highlights an association between DNA methylation, circa-
dian rhythm and the development of cancer. As mentioned
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above, epigenetics and chromatin remodelling play a role
in controlling the transcription of clock gene machinery.
Interestingly, a reciprocal relationship has also been uncov-
ered whereby the clock can impart some control on DNA
methylation—cells with a dysfunctional clock system dem-
onstrate aberrant 5-methylcytosine expression [98]. It is
well-established that circadian disruption results in sub-
stantial health consequences, numerous studies now indi-
cating that shift workers suffer a higher incidence of cancer
(reviewed in [99]). DNA hypermethylation has been linked
with several cancers and interestingly studies now show
aberrant DNA methylation patterns in every core clock
gene in a variety of malignancies [100–103] Together, these
findings suggest the existence of a pathogenic loop consist-
ing of circadian rhythm disruption, altered DNA methyla-
tion and the development of cancer. Whether or not these
changes in methylation are a cause or an effect of circadian
rhythm deregulation is still unknown. This observation, to-
gether with the study highlighted above demonstrating
maternal transmission of circadian gene hypermethylation
and hepatic fibrosis, suggests the potential for a similar
disordered circuit to exist and contribute to the pathogenic
wound healing response. Alterations in genes involved in
circadian rhythm homeostasis may lead to DNA hyperme-
thylation (or vice versa), with the subsequent manifestation
of organ fibrosis. This intriguing area of research certainly
warrants further in-depth investigation.
Epigenetic control of macrophage phenotype
Although many of the studies highlighted in this review
primarily focus on the direct role of epigenetics in control-
ling the myofibroblast phenotype, it is also emerging that
epigenetic regulation of inflammatory cells such as macro-
phages may contribute to the pro-fibrotic environment.
Macrophages not only play a key role in response to injury
but also coordinate the wound healing response by con-
trolling fibroblast activation. Macrophages are the main
source of the pro-fibrotic growth factor TGF-β1 which
drives fibroblast differentiation and ECM production
[104]. In physiological wound healing, macrophages are
cleared from the site of injury via apoptosis, but in fibrotic
tissue, sustained macrophage activation may play an im-
portant role in sustaining myofibroblast activation via the
exaggerated production of TGF-β1. Specifically, the early
inflammatory response is driven by M1 macrophages that
are important in clearing infection and necrotic tissue
whilst the wound healing response is modulated by M2
macrophages [105]. In the context of fibrosis, exaggerated
tissue injury may result from excessive M1 activation,
whilst inappropriate M2 activation may drive exaggerated
myofibroblast responses.
A relatively novel area of research regarding the epigen-
etic regulation of macrophage polarisation and its potential
contribution towards fibrosis is emerging in the context of
cardiac fibrosis. A recent article by Kim et al. alludes to
this. The study identifies a pro-inflammatory role for M1
macrophages, whilst suggesting that the M2 type play a
role in coordinating the fibrotic response. In a rat myocar-
dial infarction model, treatment with the DNA methylation
inhibitor 5-aza increased the number of M2 macrophages
whilst simultaneously decreasing the number of M1 mac-
rophages. This elevation of M2 type cells was associated
with improved left ventricular function and a reduction
of cardiac fibrosis [65]. Given that M2 macrophages are
a source of TGF-β1 caution should be exerted when
interpreting these findings. This macrophage phenotype
appears to play more of a modulatory role in wound
healing, and these potential contradictory roles of macro-
phages may arise due to the ability of these inflammatory
cells to assume a wide spectrum of functional phenotypes
determined by their microenvironment [106]. Macro-
phages appear to be important orchestrators and effectors
of tissue repair, altering their function and phenotype to
meet the needs of the healing tissue [105].
This work does, however, highlight an important link
between epigenetics and macrophage differentiation. In
addition to this, it identifies a potential pathological pro-
fibrotic contribution of DNA methylation through its
effects on macrophages and that inhibiting this process
with 5-aza can reverse these effects.
The suggestion that macrophage phenotype is con-
trolled by epigenetics is further supported by work on
adipose tissue. Obesity is associated with a switch from
alternatively activated anti-inflammatory M2 macro-
phages to classically activated pro-inflammatory M1
type. Interestingly, results demonstrate that the switch
from M2 to M1 in ob/ob mice is correlated with an in-
crease in DNMT3B expression [107]. They also showed
that DNMT3b knockdown is sufficient to induce M2
macrophage polarisation. Furthermore, knockdown of
DNMT3b had important physiological effects in improv-
ing adipocyte insulin signalling.
Taken together, these findings suggest a relatively novel
mechanism of epigenetic control of fibrosis through macro-
phage polarisation.
Conclusions
Collectively, these findings strongly support the idea
that alterations in DNA methylation have a substantial
impact on fibroblast phenotype and promote the differ-
entiation to pathological, scar-forming myofibroblasts.
Novel findings also implicate DNA methylation in
shaping the inflammatory phase of the wound healing
response and influencing progression to fibrotic disease.
Various components of the methylation machinery pose
as potential therapeutic targets and refinement of such
novel approaches will be achieved through increasing our
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understanding into the gene-specific modifications that
occur during the pathogenesis of fibrotic diseases.
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